Claims for Patent: 9,370,444

Summary for Patent: 9,370,444

Title:	Subconjunctival conformer device and uses thereof
Abstract:	The present invention provides a device for use in an eye with elevated intraocular pressure or glaucoma, the device comprising a subconjunctival conformer shaped to conform to the eye wall and a fluid director that directs or facilitates the flow of intraocular fluid out of the eye and into the subconjunctival or retrobulbar space. The present invention also provides a method of lowering intraocular pressure using the device of the present invention.
Inventor(s):	Cunningham, Jr.; Emmett T. (Hillsborough, CA)
Assignee:
Application Number:	13/272,030
Patent Claims:	1. A device for use in an eye with elevated intraocular pressure or glaucoma, the device comprising a subconjunctival conformer comprising: a. a bowl-shaped shell, configured to be placed over or in proximity to a drainage site, comprising: a proximal rim configured to contact a scleral surface at the eye wall upon positioning said bowl-shaped shell between the sclera and conjunctiva, and a distal convex outer surface configured to contact the conjunctiva, thereby creating and/or maintaining a permanent subconjunctival space in an interior of the bowl-shaped shell; and b. a fluid director having a proximal opening and a distal opening, and wherein the fluid director: i. is configured to conform to the scleral surface; ii. extends from a drainage opening on the distal convex outer surface of the bowl shaped shell, wherein a wall of the bowl-shaped shell is continuous with a wall of the fluid director, and the proximal opening is physically continuous with the drainage opening on the distal convex outer surface of the bowl-shaped shell and the distal opening is positioned outside the bowl-shaped shell; and iii. is configured to receive and direct subconjunctival flow of intraocular fluid so that the direction of flow is from the interior of the bowl-shaped shell through the opening on the distal convex outer surface of the bowl-shaped shell, through the proximal opening in the fluid director, and through the distal opening in the fluid director, thus directing the intraocular fluid away from the drainage site to a subconjunctival space or a retrobulbar space. 2. The device of claim 1, wherein the fluid director has a tubular shape. 3. The device of claim 1, wherein the fluid director has a lumen adapted and configured for diverting subconjunctival flow of intraocular fluid from anterior or posterior chambers or the vitreous cavity to the subconjunctival space at a pars plana or retrobulbar space. 4. The device of claim 1, wherein the device is implantable. 5. The device of claim 1, wherein the device is constructed of a bioerodible material. 6. The device of claim 5, wherein the bioerodible material is selected from the group consisting of polyester, polyorthoester, polyanhydride, polylactic, polyglycolic, polyvinyl acid polymer, polytetrafluoroethylene, fluorinated polymer, flexible fused silica, polyolefin, polyamide, parylene, composite of carbohydrates, polysaccharides, collagen, and combination thereof. 7. The device of claim 1, wherein the device is constructed of a non-bioerodible material. 8. The device of claim 7, wherein the non-bioerodible material is selected from the group consisting of titanium, stainless steel, cobalt-chromium-nickle-molybdenum-iron alloy, nickel-titanium alloy, tantalum, metal, silicone, silicone polymer, polyurethane, plastic, acrylic polymer, or any combination thereof. 9. The device of claim 5 or 7, wherein the material is smooth, textured, or corrugated. 10. The device of claim 1, wherein the device is constructed of multiple polymeric layers of bioerodible and/or non-bioerodible materials. 11. The device of claim 1, wherein a surface of the device is porous with a mesh or matrix design. 12. The device of claim 1, wherein the device is adapted and configured to be placed between the conjunctiva and the scleral surface of the eye. 13. The device of claim 1, further comprising a drug-eluting coating. 14. The device of claim 13, wherein the coating minimizes inflammation, scarring, fibrosis, and/or infection. 15. The device of claim 13, wherein the drug is an anti-inflammatory agent, anti-proliferative agent, anti-scarring agent, anti-microbial agent, antiseptic, intraocular pressure lowing agent, or vitreolytic agent. 16. The device of claim 15, wherein the anti-inflammatory agent is selected from the group consisting of corticosteroids, immunosuppressive agents, non-steroidal anti-inflammatory drugs, anti-inflammatory proteins, peptides, or nucleic acids, and combinations thereof. 17. The device of claim 15, wherein the anti-proliferative agent is selected from the group consisting of a corticosteroid, an immunosuppressive agent, mitomycin, 5-fluorouracil, heparin, anti-proliferative proteins, peptides, or nucleic acids and combinations thereof. 18. The device of claim 15, wherein the anti-scarring agent is mitomycin or 5-flurouracil. 19. The device of claim 15, wherein the anti-microbial agent is selected from the group consisting of antibiotics, antivirals, antifungals, and antiparasitics. 20. The device of claim 15, wherein the intraocular pressure lowing agent is selected from the group consisting of an adrenergic agonist, cholinergic agonist, beta-blocker, carbonic anhydrase inhibitor, prostaglandin analogue, and alpha-adrenergic agonist. 21. The device of claim 15, wherein the vitreolytic agent is selected from the group consisting of a dispase, urea, collagenase, hyaluronidase, plasmin, microplasmin, chondroitinase, a protease, and combinations thereof. 22. The device of claim 1, further comprising a securing structure adapted and configured for suturing and fixating the device to the sclera. 23. The device of claim 22, wherein the securing structure is selected from the group consisting of: a ring, a plurality of teeth, and a flange-like structure. 24. The device of claim 23, wherein the flange-like structure is sized and shaped to fit on the surface of the sclera at the pars plana so as to prevent the device from dislocating or migrating. 25. The device of claim 1, wherein the device is used in combination with eye surgery. 26. The device of claim 25, wherein the eye surgery is trabeculectomy. 27. The device of claim 1, wherein the device is adapted and configured to be placed in connection with one or more filtering or shunting devices to enhance and/or direct subconjunctival flow of intraocular fluid from the anterior or posterior chambers or the vitreous cavity of the eye to the subconjunctival space or the retrobulbar space. 28. The device of claim 27, wherein the shunt device is an Ahmed valve, Molteno valve, or Krupin slit valve. 29. The device of claim 27, wherein the device is placed over, below, around, or adjacent to the filtering or shunting device to minimize scarring, fibrosis, inflammation, and/or infection, and facilitate the egress of intraocular fluid from the filtering or shunting device. 30. The device of claim 1, wherein the device is used in combination with another device for monitoring intraocular pressure over a period of time. 31. The device of claim 1, wherein subconjunctival flow of intraocular fluid drains to the subconjunctival space or retrobulbar space at a sufficient flow rate to reduce intraocular pressure. 32. The device of claim 1, wherein the device is used for treating glaucoma. 33. A method of lowering intraocular pressure, the method comprising: a. introducing into an eye with a drainage site a device that comprises a subconjunctival conformer, wherein the subconjunctival conformer comprises: i. a bowl-shaped shell, wherein the bowl-shaped shell comprises a proximal rim, a distal convex outer surface, and an interior of the bowl-shaped shell; and ii. a fluid director having a proximal opening and a distal opening that is configured to conform to the scleral surface and extends from a drainage opening on the distal convex outer surface of the bowl-shaped shell, wherein the proximal opening is physically continuous with the drainage opening on the convex outer surface of the bowl-shaped shell and the distal opening is positioned outside of the bowl-shaped shell; b. positioning the bowl-shaped shell over or in proximity to the drainage site; c. contacting a scleral surface with the proximal rim of the bowl-shaped shell; d. contacting the conjunctiva with the distal surface of the bowl-shaped shell; and e. directing subconjunctival flow of intraocular fluid from the interior of the bowl-shaped shell through the fluid director to a subconjunctival space or a retrobulbar space, wherein the subconjunctival flow is directed from the interior of the bowl-shaped shell, through the proximal opening of the fluid director, and through the distal opening of the fluid director. 34. The method of claim 33, wherein the device creates and/or maintains a permanent subconjunctival space between the conjunctiva and the scleral surface. 35. The method of claim 33, further comprising an eye surgery trabeculectomy, wherein the eye surgery trabeculectomy produces the drainage site. 36. The method of claim 33, further comprising placing the device in connection with a filtering and/or shunt device. 37. The method of claim 36, further comprising placing the filtering and/or shunt device to enhance and/or direct intraocular fluid from a region of the eye selected from an anterior chamber, posterior chamber and a vitreous cavity. 38. The method of claim 36, further comprising placing the filtering and/or shunt device to enhance and/or direct subconjunctival flow of intraocular fluid to the subconjunctival space or the retrobulbar space. 39. The method of claim 36, wherein the bowl-shaped shell is placed over, below, around, or adjacent to the shunting device. 40. The device of claim 1, wherein the subconjunctival space is at the pars plana.

Details for Patent 9,370,444

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2030-10-12
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2030-10-12
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2030-10-12
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2030-10-12
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2030-10-12